Month: April 2018

Doe Deere, Lime Crime founder, with her bold eye make-up and striking hair is not an introvert and neither is her brand. Lime Crime is active on Instagram. She believes that unique is the meaning to the world cult, and that you are providing something that can’t be provided by someone else. Crime Lime has been doing that since 2008, the market has changed a great deal and Doe Deere thinks it is important to be an individual and stand out.

Cruelty Free and Vegan 100%

These things reflect the personal attitude of Doe Deer when it comes to animal testing and the goals she has for Lime Crime. The brand is cruelty free and vegan because they do a lot of charity work related to animals.

Overcoming Entrepreneurial Mistakes

Doe Deere believes that mistakes are part of being an entrepreneur, the important thing is what is learned from those mistakes. There have been ups and downs for Lime Crime but they have improved as a company because of it.

Beauty Trends

Ultraviolet, the color of the year for Pantone is desirable. Doe Deere believes the color is the ultimate for the unicorn inspired brand. The company looks to expand into lilac, lavender and various other purple shades during 2018 beginning with the Venus three palette of eyeshadow.

Advice for Young Woman Starting Out in the Beauty Business

Doe Deere recommends that young women just starting out should always be on the lookout for things that are missing in the market and continuously think about innovation. It is important to consider what you like, and what you want and make it a reality. Always listen to yourself.

What Goes Into Creating Lime Crime Collection Items?

All of the formulations for Lime Crime was originally done by Doe Deere herself, but now there is a team that does the formulations. Products only make it if they are something everyone believes in, if it doesn’t work for the team creating it then it doesn’t make it into the line.

Lime Crime Creator’s Obsession with Whimsical Things

Doe Deere credits the times allowing for self expression for her love of all things whimsical. People are starting to realize that there is no need to conform thanks to social media. It is awesome to be different. The company gives unicorns a lot of focus since the brand is about owning being different and the creatures are unique.

Make-up Palette Popularity

The array of different colors means you can use one box to tell a story which is inspiring. The colors are focused to give a specific look. Grunge was the focus of the first Venus and purples, lavenders and neutrals are the focus of the last Venus. The mix allows the shades to be worn daily. Learn more: http://doedeerefam.com/

Kerrisdale Capital Management’s Sahm Adrangi issued a report in support of his decision to short the stock of Proteostasis Therapeutics, Inc. This is a biopharmaceutical firm who has a drug in development called PTI-428. The value of this company largely depends on the success of this one drug which is being clinically studied to treat cystic fibrosis. Their stock doubled when the FDA designated PTI-428 as both a Breakthrough Therapy and as an Orphan Drug. However, the analysts working for Sahm Adrangi say that this drug is in all likelihood ineffective and will never be released.

There are two main problems with PTI-428, Sahm Adrangi says. The first is that his analysts have shown that the pattern of data for this candidate drug is of low quality. Secondly, he says that Proteostasis Therapeutics has been omitting some critical information in their public disclosures. He said this company released their Phase 2 clinical trial results in December 2017 which claimed that PTI-428 showed improved lung function over the results of a placebo.

However, Sahm Adrangi says that once his analysts dug into the details they saw that these Phase 2 results are not nearly as meaningful as investors have been led to believe. He said the drug didn’t actually improve patient’s health, it was that the four patients who had taken placeboes did very poorly which made PTI-428 look a lot more effective than it actually is. Phase 1 had shown the PTI-428 didn’t improve lung function in any meaningful way and in reality that was what Phase 2 confirmed. Later in the day after he issued his report Sahm Adrangi had held a teleconference in order to further explain his negative position on Proteostasis Therapeutics.

After graduating from Yale University with a bachelor of arts in economics, Sahm Adrangi found his first position at Deutsche Bank. He went on to work for two other investment firms before founding Kerrisdale Capital Management and starting his own hedge fund. He says his personal investment style is value. His company now manages $300 million which is mostly in long-term value investments. The rest is shorting the stocks of companies that he sees as overvalued.

Jeff Yastine believes when it comes to cybersecurity the best option is to follow the money. He also uses this philosophy as a basis for investments. He says when there is a lot of money being funneled into stocks the price will increase. He also feels this makes his job as an investor much simpler and easier. This philosophy relates extremely well in regards to cybersecurity. Jeff Yastine has spoken of the $7.6 billion in investments made in startups in comparison to just $3.8 billion from the previous year. Venture capitalists have become interested in 548 companies and this is where their money is going. There has been an increase in investments of 17 percent since 2016. Follow Jeff Yastine on Medium.

There was a prediction Jeff Yastine has spoken of made several years back. The expectations were the money being spent on cybersecurity would undergo a sharp increase. The figure predicted was twelve to fifteen percent until the year 2021. The prediction also stated the world would be spending in excess of a trillion dollars on cybersecurity. Jeff Yastine sees the opportunities present in the cybersecurity sector. A good example was the breach experienced by Equifax. Approximately 145 million people were placed at risk due to the information stolen from the agency through the computers.

There have been numerous flaws identified in company processors. They have been given the nicknames of Spectre and Meltdown. Jeff Yastine believes this guarantees a lot more money will be spent on cybersecurity now and in the future. The Total Wealth portfolio contains a lot of cybersecurity stocks for a reason. During the past four months alone aggregate has shown gains as high as fifty percent. Jeff Yastine has already recommended ETFMG Prime Cyber Security. The shares have shown an increase of twelve percent since August. Jeff Yastine continues to tell investors about the opportunities currently available in the cybersecurity realm. Visit stockgumshoe.com to know more.

There is a lot of speculation regarding the current value of cryptocurrency. The blockchain technology has already been subjected to experimentation by investors to improve and enhance the security features. Since the news has broken regarding the many security issues being experienced by prominent companies the firms manufacturing digital sensors and chips have been impacted. They are investing in new fixes to prevent potential flaws in the future. Jeff Yastine is encouraging investors to take a serious look at the cybersecurity sector because he believes these investments will have a nice return. Check: https://angel.co/jeff-yastine

Scott Rocklage is one of the worlds most acclaimed biochemists and he is also one of the medical industries leading businessmen. His medical investment venture capital firm 5AM ventures, is a prime source of funding resources for organizations and entities conducting groundbreaking research all over the globe. It is this research that is paving the way to new treatments and finding the foundations of future cures for some of the worlds worst medical conditions. Most recently 5AM ventures joined forces with other funding partners to generate a new resource pool for Expansion Therapeutics. The research and development company is leading the charge to find a treatment for a condition that could save the lives of millions, Myotonic dystrophy type I.

Myotonic dystrophy type I or DM1 as it is known in medical research circles, is the leading cause of muscular dystrophy in adults. There is no known treatment program for DM1 although it is known that in a great percentage of cases the condition is hereditary and its effects can increase and manifest faster with each subsequent generation. For this reason, entire family lines are at risk of being obliterated within a few generations unless something is done to find a cure.

Expansion Therapeutics undertook the funding campaign with the help of Novartis Venture Fund, Sanofi Ventures, Alexandria Venture Investments, RA Capital Management, Kleiner Perkins, and of course Scott Rocklage and 5AM Ventures. The campaign was an overwhelming success and garnered more than $55.3M for the purposes of continuing to search for treatment options and potentially a cure for DM1. The funding pool will allow the work that expansion Therapeutics is doing on DM1 research to continue for at least the foreseeable future.

Scott Rocklage is a man who loves to help find cures for conditions and disease such as DM1. This is more than just a career point for him, it as passion. He has spent his entire life working to help others and search for ways to make their lives better. He started his career at The University of California, Berkeley, where he worked hard and earned a Bachelor of Science in Chemistry with honors. He then went on to earn his Ph.D. in Chemistry from MIT, where he had the chance to work in the laboratory of Richard R. Schrock, the 2005 winner of the Nobel Peace Prize for Chemistry.

He started working with 5AM Ventures in 2003 first as a venture partner, and later as a managing partner beginning in 2004. He works out of the 5AM Ventures Boston Office and lives with his wife, Patty Rocklage, acclaimed Therapist, outside of the city.

There are many things that could put us at the level of success that we want. We could practice a skill and charge people for delivering a service. We could also start a business. We could also just join stocks trading. What you should consider, though, when you want as much profit as you can is to consider putting your money in many baskets and not just in one. This is one of the few things that Paul Mampilly does himself, and the level of success that he’s in right now could be attributed to such strategy. View Paul Mampilly’s profile at linkedin.com

The Newsletter Innovation

We know that Paul Mampilly is the American investor and former hedge fund executive that’s able to help companies build their asset portfolio and increase their chances of income. As a matter of fact, the kind of success that Mr. Paul Mampilly has received is an indication that he has something to say that’s highly valuable and profitable for the entire global market. Right now, an outstanding achievement that he received is also the fact that he has started a successful newsletter that’s able to generate a lot of help and assistance to those who need successful financial advice that works. Also, it should be said that the expertise, knowledge, and experience that Mr. Paul has been through all his career has been shared in his newsletter that right now has about 90,000 subscribers, which would still expect to grow and increase its following.

The Man In India

There are many reasons why Paul Mampilly is the successful investor and venture capitalist that he is right now, but what could be the reasons? Some of them could have to do with his origins and educational background. Secondly, Paul is born in India and moved to United States to practice his career, and this background could be the reason why he has the kind of unique perception that could shape his financial decisions. The 25 years of financial experience is also a good training background of why he stands out to be a successful portfolio manager.

The Awards

The career of Paul Mampilly has been shaped by his dedication to quality service, which is justified by the series of awards that he earned. One of the best awards he got is the Templeton Foundation award for his remarkable investment program. This award could also be the reason why he’s one of the most sought after finance people who are able to be featured on reputable news networks, including Bloomberg TV and CNBC.